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and	a	quality	of	 life	questionnaire	 (Dermatological	Life	Quality	 Index).	There	was	no	statistical	difference	be-
tween groups. There was a trend of favorable response particularly in the hemibody treated with clobetasol.
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Psoriasis	 is	 a	 chronic,	 immune-mediated	 and	 ge-
netic	based	dermatoses,	characterized	by	accelerated	
cell	proliferation	of	keratinocytes	and	by	 the	 inflam-
mation that originate parakerotosic scales.	1,2 Its cause 
is	still	unknown.	However,	 it	 is	known	that	its	onset	
or	 exacerbation	 depend	 on	 several	 factors:	 genetic,	
immunological,	 environmental,	 and	biochemical,	 be-
sides	the	influence	of	emotional	factor.	2,3




and are candidates for topical treatment. Even patients 
with extensive forms of the disease often continue with 
resistant	 lesions	 after	 systemic	 treatment	 and	 require	
association with topic medications. Treatment is also 
problematic due to the fact that disease manifestations 
are	not	uniform	and	due	to	adhesion	difficulties.	5,6 In 
the	case	of	 topical	 treatments,	 it	occurs	mostly	due	to	
cosmeceutical issues (drugs that have unpleasant odor 
or	that	dirty	the	clothes).	7,8	Therefore,	we	sought	a	ve-
hicle option that could increase adherence to treatment. 
The	use	of	clobetasol	in	lacquer	still	hadn’t	been	evalu-
ated in skin lesions and was expected to eliminate the 
mentioned cosmetic factors that occur with certain oint-
ments.
This	 study,	 developed	 after	 receiving	 authoriza-
tion from the Ethics Committee of the Medical School 
(FCM)/	Unicamp,	was	prospective	and	double-blind.	






Only one of the bottles contained the active ingredient 




es the extent and severity of psoriasis. With the assess-
ment	of	PASI	it	is	possible	to	classify	psoriasis	as	mild,	
moderate and severe based on skin manifestations. 
The disease is considered mild when indexes are <10 
and	moderate	to	severe	when	they	are	>10.	1,9  Patients 
assisted by the Dermatology Department of the State 
The	study	included	40	patients,	24	men.	Mean	age	
was	53.9	years,	ranging	between	18	and	81	years.
In	 the	 initial	 consultation,	 after	 prior	 consent	 by	
volunteers,	 the	 attending	 physician	 determined	 the	
clinical	 index	 of	 each	 hemibody,	 based	 on	 PASI	 cri-
teria. The same procedure was conducted in consul-
tations in Day 30 and Day 60 of treatment. Patients 
also	 answered,	 in	 each	of	 these	 consultations,	 to	 the	
Figure 1: Distribution	of	PASI	comparing	the	
evolution of hemibodies exposed to clobetasol 
in	lacquer,	in	ointment	and	its	control
Figure 2: Distribution of DLQI comparing the 
outcomes	of	patients	who	used	lacquer	and	those	
using the ointment 
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University of Campinas Medical School (FCM-UNI-
CAMP),	presenting	mild	 to	moderate	psoriasis	 at	 the	
beginning	of	the	protocol,	participated	in	the	research.	
The study selected individuals with a minimum age of 
18	years,	with	no	use	of	 topical	 treatments	or	sudden	
changes of clinical presentation for at least two months. 
Patients with severe form of the disease at baseline or 
known	allergy	to	lacquer	were	excluded.
self-administered	 questionnaire	 DLQI	 (Dermatologi-
cal	Life	Quality	Index)	used	to	assess	quality	of	life.10
In	the	end,	clinical	rates	obtained	were	confronted	
with the information declared by the pharmaceutical 
and the analysis of the DLQI values was performed. 
For	 the	comparative	analysis	of	 the	 results,	we	used	
the SPSS 15.0 program.
Three patients in each group did not complete the 
proposed two months of treatment. In the group using 
lacquer	as	vehicle,	two	patients	reported	severe	pruri-
tus associated with erythematous lesions after a few 
days	of	application	of	the	lacquer,	and	another	patient	
was withdrawn due to clinical worsening. Use of lac-
quer	 in	 extensor	 areas,	 such	 as	 knee	 and	 elbow,	has	
also	been	criticized	by	two	patients	who	completed	the	
study,	due	 to	 the	occurrence	of	dryness,	 breaking	of	
the	film	and	and	desintegration	of	the	product.	In	the	
group	using	petrolatum	 as	 vehicle,	 two	patients	 left	
the protocol and another presented allergy referred as 
eyelid	swelling	and	pruritus	on	the	face,	which	led	to	
the suspension of topical use.
Clinical rates of each hemibody showed an im-
provement tendency in both groups of patients. This 
tendency was also observed even in hemibodies in 
which	only	the	vehicle	was	applied,	according	to	the	




to	 lacquer	 showed	 a	 higher	 improvement	 tendency	
compared with that observed in control hemibodies. 
Observing	the	mean,	this	tendency	was	slightly	high-
er	in	hemibodies	treated	with	clobetasol	ointment.	As	
standard	deviations	 touch,	 there	was	 no	 statistically	
significant	difference	between	groups	(Figure	1).	Ten-
dency of improvement in the hemibody exposed only 
to	vehicle	may	represent	a	placebo	effect	of	topical	use,	
but the possibility of absorption of the active ingredi-
ent	 in	both	vehicles	and	hydrating/moisturizing	po-
tential of the ointment vehicle should be considered.
Results obtained with DLQI are presented in 
figure	 2,	whose	 distribution	 shows	 that	 there	was	 a	
tendency	 toward	 improvement	 of	 quality	 of	 life	 in	
both	 groups,	 with	 no	 statistical	 difference	 between	
them.
Results	 suggest	 that	 use	 of	 clobetasol	 in	 lacquer	





Marcos,	 owner	 of	 the	 Botica	 Erva	Doce,	 	 where	 the	
products were manufactured.  q
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